Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPU: Nivolumab + ipilimumab ± UV1 in malignant pleural mesothelioma
2022-502604-67-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in pleural mesothelioma comparing Nivolumab + ipilimumab + UV1 vaccine + sargramostim with Nivolumab + ipilimumab (2 arms). Primary endpoint: Progression-free survival by BICR (modified RECIST). Planned start Feb 2023; status: authorised.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2022-502604-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502604-67-00.